Routine prophylaxis to prevent bleeding or reduce frequency of bleeding episodes in adults & childn w/ hemophilia A (congenital factor VIII deficiency) w/ or w/o factor VIII inhibitors.
SC Inj on abdomen, upper outer arm or thighs. Recommended loading dose: 3 mg/kg once wkly for the 1st 4 wk, followed by maintenance dose of either 1.5 mg/kg once wkly, or 3 mg/kg every 2 wk, or 6 mg/kg every 4 wk.
Not to be administered into areas where skin is red, bruised, tender or hard, or areas w/ moles or scars. Discontinue treatment w/ bypassing agents the day before starting therapy. Thrombotic microangiopathy & thromboembolism associated w/ treatment & activated prothrombin complex conc. Immunogenicity. Lab coagulation test interference eg, aPTT, Bethesda assays (clotting-based) for FVIII inhibitor titers, 1-stage, aPTT-based, single-factor assays (eg, FVIII activity), aPTT-based activated protein C resistance, activated clotting time. Pregnancy & lactation.
Sign Out
